S * Bio announced the successful development of a patented oral drug, code-named SB 15 18, which will be used to treat myeloproliferative diseases and some types of hematological tumors.
Myelodysplastic disease is a rare blood tumor. Abnormal proliferation of bone marrow cells leads to excessive red blood cells and platelets and bone marrow fibrosis. This new drug prevents the unnatural proliferation and division of bone marrow cells by interfering with the signals that cause abnormal proliferation.
Preliminary experiments show that the new drug can inhibit the proliferation of bone marrow cells and resist tumors in vitro and in vivo.
Dr. Carlson, President of S * Bio Company, pointed out that patients with myeloproliferative diseases lack targeted and long-term treatment methods. Once the new drug is successfully developed, it will provide a glimmer of hope for these patients.
This is the second major breakthrough made by S * Bio in the research and development of anticancer drugs in recent 12 months. The first anticancer drug developed by Singapore Laboratory was also developed by S * Bio, and the first phase of clinical trial was just started in June this year.
The new anticancer drug SB 15 18 is expected to start a phase I clinical trial in the first half of next year. If the experiment is successful, the drug will be on the market in five years.